Stockreport

Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant

Intersect ENT, Inc.  (XENT) 
Last intersect ent, inc. earnings: 2/24 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intersectent.com/investor-relations
PDF MENLO PARK, Calif. & BARCELONA, Spain--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients [Read more]